What is the RNA stock price prediction for next 2 weeks?

According to our price prediction algorithm,Atrium Therapeutics, Inc. (RNA) price will be around $12.74 in the next 2 weeks. This means it will decrease by -1.017871017871006 from the last closing price. This prediction may vary from other time period filters for RNA stock.

What can be the highest Possible price of RNA stock in next 2 weeks?

Our forecast algorithm expects that in 2 weeks, RNA can achieve the highest price of $13.43 which is 4.380780149817946 higher than last closing price. This prediction may vary from other time period filters for RNA stock.

What can be the lowest Possible price of RNA stock in next 2 weeks?

As per the forecast and algorithmic analysis, RNA stock price can be as low as $11.96 which is -7.03369414938073 lower than the current price in the next 2 weeks. This prediction may vary from other time period filters for RNA stock.

Will RNA stock go high in the next 2 weeks?

No, our stock forecasting algorithm shows that RNA stock will lose-1.017871017871006 in the next 2 weeks. This prediction may vary from other time period filters for RNA stock.

What is RNA stock last closing price?

Last closing price of RNA stock was $12.87.

What is RNA stock price prediction?

RNA stock price prediction means predicting the future closing prices of RNA stock based on its past data. Our forecasting algorithm uses various machine learning and deep learning techniques to forecast the future behavior of RNA stock in a certain time period.

How we predict RNA stock future prices?

If you are searching for RNA stock forecast, analysis or price prediction, then you might be wondering what Atrium Therapeutics, Inc. (RNA) will do in the future. Our RNA price predictions are based on various Machine Learning based algorithms with an aim to try and predict future price movements. This RNA price prediction will likely answer most of your questions.

How frequent we update RNA stock predictions?

We are updating the forecasts for the RNA stock on daily basis.

Is using ML forecasting for RNA stock a good way?

Yes. Stock Price Prediction is one of the most exciting applications of Machine Learning. By leveraging data from the past, it is possible to use forecasting models to make accurate predictions about future stock prices. This can be incredibly beneficial for investors and traders, as it gives them the ability to make more informed decisions about when to buy and sell. Investing in the stock market can be a risky endeavor, but leveraging Machine Learning can make it a bit less daunting and more profitable.

Is the Prediction for RNA stock same for all the time periods?

No, the prediction for RNA stock is not same for all time periods. The forecasts may vary depending on the differences in the time period.

Atrium Therapeutics, Inc. Stock Forecast and Stock Price Prediction

Stock Forecast Chart

Stock Price Prediction Summary

Closed Price$12.87-4.88%Since 2 Weeks

Predicted Price$12.74-1.02%For 2 Weeks

Upper Predicted Price$13.434.38%For 2 Weeks

Lower Predicted Price$11.96-7.03%For 2 Weeks

Forecast Score Based on 2 Weeks

Based on our forecast, the price of RNA will decline by -1.02% over the next 2 Weeks and hit $12.74 by Monday, May 18, 2026. In that time frame, RNA's share price is expected to range between $11.96 and $13.43.

BearishAverageBullish

Date	Predicted Lower	Predicted	Predicted Upper
May 18, 2026	11.96	12.74	13.43
May 15, 2026	11.81	12.62	13.36
May 14, 2026	12.14	12.83	13.60
May 13, 2026	11.96	12.66	13.38
May 12, 2026	12.16	12.88	13.61
May 11, 2026	12.04	12.80	13.47
May 8, 2026	11.94	12.68	13.43
May 7, 2026	12.12	12.90	13.62
May 6, 2026	12.01	12.73	13.49
May 5, 2026	12.24	12.94	13.67

RNA shares fell -4.17% in Monday, May 4, 2026's trading session, dropping from a previous close of $13.43 to move at $12.87. The stock demonstrated notable intraday movement (see RNA's key stats for a full breakdown), fluctuating between $12.81 and $13.57, a +5.93% trading range. While recent weeks have seen some volatility, RNA has managed to secure a -10.69% drop over the past 2 weeks. The downward price movement was accompanied by decreased trading volume, with approximately 144.45K shares changing hands, 107.69K fewer than the previous session. This amounted to $1.86M in total market activity.

Will RNA Continue Its Upward Trend?

According to analyst ratings and projections for RNA, Atrium Therapeutics, Inc. shares are anticipated to increase by +4.20%, potentially reaching $13.43 per share by May 18, 2026. Short-term technical indicators currently suggest a neutral sentiment for RNA. For deeper insights, view our sentiment analysis on AAPL covering social and institutional perspectives. However, the stock has recorded 17 positive trading days within the past 30 sessions. Based on the RNA stock forecast, now is a good time to buy RNA stock because its current trading price is +1.03% above our predicted value, hinting at a possible undervaluation. For deeper insights, view our sentiment analysis on RNA covering social and institutional perspectives.

RNA Technical Momentum: Overbought, Oversold, or Neutral?

An analysis of Relative Strength Index (RSI) indicators provides insight into RNA's momentum. Short-term RSIs (9, 14, and 20-day figures ranging from 42.93% to 43.97%) suggest the stock is in a neutral to slightly bearish momentum phase.Insights into RNA's shareholder base show how institutional investors are positioning themselves during these momentum shifts

Atrium Therapeutics Short-Term Forecasts

RNA Forecast For Next 5 Days

Our algorithm anticipates Atrium Therapeutics (RNA) stock could hit $0.35 by May 11, 2026. This represents a -97.25% rise from today's price, following a +0.17% change over the past five days.

RNA Forecast For Next 30 Days

Based on analysis of market trends, the outlook for Atrium Therapeutics, Inc. (RNA) stock over the next 30 days is largely negative. Price forecasts suggest an average target of $0.24, which would mean a -98.14% decrease from the current price of $12.87. Projections for this period range from a high of $12.13 to a low of $0.00.

RNA Forecast For Next 90 Days

Our proprietary market analysis suggests predictions for Atrium Therapeutics's price over the next three months point to a drop. RNA stock is expected to peak at $17.88 on May 06, 2026 before potentially dipping to $4.47 on Aug 04, 2026. On average, RNA is likely to trade around $11.30 in the coming 90 days.

Atrium Therapeutics Stock Forecast 2025

Based on our predictive models, Atrium Therapeutics (RNA) is expected to trade between $0.00 and $17.88 throughout 2026. This would result in an average price of $8.69, potentially offering investors a -32.48% return from current levels.

Atrium Therapeutics, Inc. Monthly Forecast 2026–2027

May 2026

According to our latest forecast models, Atrium Therapeutics, Inc. (RNA) is positioned to show a strong performance in May 2026. The price is predicted to move between $8.69 and $17.88, settling at an average of $13.02. This could translate to a +1.17% gain.

June 2026

Based on current market signals, Atrium Therapeutics, Inc. is projected to trend june 2026. We forecast a trading range from $7.64 to $15.38, with a likely average price of $11.66. Investors could expect a potential return of -9.40%.

July 2026

Our predictive algorithms indicate Atrium Therapeutics, Inc. stock may see a shift in July 2026. The expected range spans $5.02–$12.81, with an average target of $10.07. This represents a cautious outlook and a possible loss of -21.76%.

August 2026

Analyzing established trends, Atrium Therapeutics, Inc. looks set to move in August 2026. Projections place the stock between $3.72 and $9.56, averaging around $7.32. This suggests a -43.12% loss from current levels.

September 2026

Market indicators suggest Atrium Therapeutics, Inc. could experience notable changes during September 2026. Prices could fluctuate within $0.77 to $8.48, with a midpoint forecast of $6.34. The stock might deliver a -50.74% loss.

October 2026

Forecasting for October 2026, models estimate that Atrium Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $6.59, averaging $6.61. This signals a cautious trajectory with potential returns around -48.64%.

November 2026

According to our latest forecast models, Atrium Therapeutics, Inc. (RNA) is positioned to show a strong performance in November 2026. The price is predicted to move between $0.00 and $4.80, settling at an average of $8.00. This could translate to a -37.84% loss.

December 2026

Based on current market signals, Atrium Therapeutics, Inc. is projected to trend december 2026. We forecast a trading range from $0.00 to $1.68, with a likely average price of $7.02. Investors could expect a potential return of -45.45%.

January 2027

Our predictive algorithms indicate Atrium Therapeutics, Inc. stock may see a shift in January 2027. The expected range spans $0.00–$0.00, with an average target of $5.73. This represents a cautious outlook and a possible loss of -55.48%.

February 2027

Analyzing established trends, Atrium Therapeutics, Inc. looks set to move in February 2027. Projections place the stock between $0.00 and $0.00, averaging around $4.54. This suggests a -64.72% loss from current levels.

March 2027

Market indicators suggest Atrium Therapeutics, Inc. could experience notable changes during March 2027. Prices could fluctuate within $0.00 to $0.00, with a midpoint forecast of $1.71. The stock might deliver a -86.71% loss.

April 2027

Forecasting for April 2027, models estimate that Atrium Therapeutics, Inc. may undergo key fluctuations. If trends hold, the stock might trade between $0.00 and $0.00, averaging $1.09. This signals a cautious trajectory with potential returns around -91.53%.

May 2027

According to our latest forecast models, Atrium Therapeutics, Inc. (RNA) is positioned to show a strong performance in May 2027. The price is predicted to move between $0.00 and $0.00, settling at an average of $0.92. This could translate to a -92.85% loss.

RNA's history of dividends and stock splits also plays a role in long-term investor confidence.